Keywords: shire, 2nd, qtr, sees, revenue, jump, costs
Shire's 2nd qtr sees 32% revenue jump, R&D costs rise 38% as candidates advance
Article | 08 August 2005
UK specialty drugmaker Shire Pharmaceuticals says that, for the second quarter of 2005, revenues jumped to $424.6 million, up 32% on the like, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
